Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Tenaya Therapeutics (TNYA) Stock Down -6.35% Today?

Why Is Tenaya Therapeutics (TNYA) Stock Down -6.35% Today?

Key Takeaways

  • Shares of TNYA fell 6.35% to $0.2874 in midday trading on November 19, sliding below the prior 52-week low of $0.30.
  • No company press release, SEC filing, analyst action, or clinical update issued today explains the decline.
  • The drop coincided with a sharp risk-off session: the S&P 500 shed about 1.4% and small caps fell roughly 2%.
  • The biotech tape was only modestly weaker, with the sector benchmark down about 0.3%, pointing to stock-specific micro-cap pressure rather than a sector catalyst.
  • Persistent overhangs include a sub-$1 Nasdaq bid-price deficiency, ongoing cash burn, and an equity value that now sits below the company's $66.8 million cash balance.
  • Volume was running modestly above its normal daily pace, with the heaviest selling concentrated in the early afternoon.
  • Traders are focused on the year-end TN-201 and TN-401 data updates and regulatory feedback on pivotal trial planning.
  • Get detailed Price Targets, Earnings history, and Forecast data on our dedicated pages.
  • Explore Trending AI Robots to see which automated strategies are performing best in the current market.

Opening Summary

Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage cardiovascular gene therapy company developing TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and the small-molecule candidate TN-301. The stock traded at $0.2874 by early afternoon on November 19, down $0.0195, or 6.35%, from the prior session's close of $0.3069. The direction was decisively lower, and the move pushed shares to their weakest level in more than a year. No verified company-specific catalyst was found for the session; the decline instead tracked a broad retreat in high-beta, speculative small caps and continued a downtrend that has erased roughly 57% of value over three months.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found. There was no new clinical readout, financing, partnership, regulatory decision, or sell-side rating change published before or during today's session that accounts for a move of this size. The only recent filings were routine Form 4 disclosures reporting share sales by the chief executive and chief medical officer to cover tax withholding on vesting restricted stock units — automatic transactions of roughly 3,200 to 3,500 shares each, far too small to move the tape.

The most plausible technical explanation is continued liquidity-driven drift in a micro-cap with thin order books. The stock has closed lower in five of the past six sessions and has lost ground in nine of the past twelve, a pattern consistent with persistent seller pressure rather than a discrete event. A single moderate-sized order can move a name this size by several percentage points: intraday turnover near $480,000 by early afternoon illustrates how little capital is required. The retreat also accelerated after shares failed to hold the $0.30 area that had acted as the floor since early November, a break that likely triggered stop-loss and momentum selling.

Persistent Overhangs Behind the Decline

While not today's news, several structural factors have weighed on sentiment for months and remain relevant to the price action. Tenaya received a Nasdaq notice in January 2026 after its closing bid stayed below $1.00 for 30 consecutive business days, and the shares have not recovered that threshold since; the listing now sits on the Nasdaq Capital Market under continued listing deficiency. With a market capitalization of roughly $65 million against $66.8 million in cash and equivalents at September 30 — and a runway management projects into the fourth quarter of 2027 — the equity is being valued at a discount to its own balance sheet, a signal of investor skepticism about the cost and probability of late-stage development.

Offsets are limited. Quarterly results on November 4 beat expectations on both lines, and regulators granted RMAT designation to TN-401 in September, yet the stock has fallen in every session since that report apart from a brief two-day bounce.

Market Context and Trading Activity

Volume reached approximately 1.7 million shares by early afternoon versus a 10-day average near 2.9 million, a pace modestly above normal for that point in the session but far from a capitulation spike. The move diverged from the biotech sector: the SPDR S&P Biotech ETF (XBI) slipped only about 0.3%, while the small-cap Russell 2000 proxy (IWM) dropped nearly 2% and the S&P 500 fell about 1.4% amid a broader de-risking tied to rate concerns and weakness in high-multiple technology names.

Technically, the picture deteriorated. Shares opened near $0.31, made a brief push toward $0.315, then sold off steadily to an intraday low around $0.28 — a fresh 52-week low beneath the November 5 trough of $0.30 — and remained pinned well below both their 50-day and 200-day moving averages. The breakdown of the $0.30 shelf is the session's most significant chart event.

News Significance Score

The score runs from 0, meaning no meaningful news and a move typical for the stock, to 100, meaning transformative news and an extreme, rare price move. Tenaya Therapeutics earns 11 out of 100.

The news component is weak: no verified catalyst was published for today's session, and the nearest material developments — the November 4 earnings beat and the September RMAT designation — are already weeks old and were followed by selling. The price component is also mild. Today's 6.35% decline was roughly 1.8 times the stock's average absolute daily move of about 3.4% over the past 60 sessions, and moves of equal or greater magnitude occurred 11 times in that span. A routine-sized move in a routinely volatile name produces a low combined score.

What Comes Next for TNYA

Attention now shifts to the company's promised year-end disclosures. Tenaya has guided to longer-term MyPEAK-1 follow-up for TN-201, including one-year Cohort 2 data and two-year durability for Cohort 1, alongside additional RIDGE-1 interim data for TN-401. Management also expects to report feedback from regulatory discussions on pivotal trial designs for both programs before the calendar turns, with the TN-301 program targeted for a company-sponsored Phase 2 trial in the second half of 2027.

Those updates carry binary risk: positive durability and regulatory clarity could reframe the development timeline, while any delay, safety signal, or requirement for a larger and costlier pivotal study would intensify financing concerns. Investors should also watch cash consumption against the projected runway, the status of the Nasdaq bid-price deficiency and any potential reverse split, and the willingness of capital markets to fund clinical-stage gene therapy. Fourth-quarter results are expected in early March 2027, with consensus centered on a modest loss per share.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection from a library of hundreds of AI-driven trading bots spanning thousands of tickers. Rather than listing every model, the section surfaces only those strategies demonstrating the strongest performance under current market conditions. Bots differ widely by strategy logic, holding period, risk controls, performance metrics, and the symbols they trade, so the featured set rotates as market regimes shift. Reviewing the current lineup is a practical way to see how automated strategies are positioned right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TNYA

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


TNYA in -7.53% downward trend, sliding for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TNYA declined for three days, in 320 of 348 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNYA as a result. In 71 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TNYA entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for TNYA just turned positive on October 28, 2026. Looking at past instances where TNYA's MACD turned positive, the stock continued to rise in 44 of 46 cases over the following month. The odds of a continued upward trend are 90%.

Following a +24.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNYA advanced for three days, in 210 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

TNYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.164) is normal, around the industry mean (3.596). P/E Ratio (-0.706) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (94.340) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. TNYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
171 Oyster Point Boulevard
Phone
+1 650 825-6990
Employees
70
Web
https://www.tenayatherapeutics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.